IMDX
BEARISHAt a glance
Key valuation, profitability, growth, and risk metrics.
AI Analysis
AI-powered fundamental assessment
Key Strengths
Key Risks
Performance Snowflake
Multi-dimensional analysis across 5 key categories
P/S and P/B metrics indicate the stock is fundamentally overpriced relative to its assets and sales.
- Price/Sales of 25.15 is excessive for a shrinking company
- Negative Price/Book ratio
- No Graham Number available due to negative earnings
Growth metrics are trending sharply downward, contradicting the 'Buy' recommendation.
- Analyst target price suggests potential upside
- Revenue growth is negative (-23.4%)
- Q/Q EPS growth is crashing (-111.8%)
Historical performance shows a pattern of value destruction and operational failure.
- 5-year price return of -97%
- Consistent failure to meet earnings estimates over 25 quarters
The F-Score confirms the company is in the 'Weak' health category.
- Current ratio slightly above 1.0
- Piotroski F-Score of 1/9
- Negative ROA of -62.66%
Dividend yield is N/A.
- No dividend history
- Zero payout capacity
Stock Price & Analyst Targets
Real-time price movements and analyst price targets
Multi-Horizon Performance vs Peers
Price momentum across 5Y → 1W horizons for IMDX and closest competitors.
| Company | 5Y | 3Y | 1Y | 6M | 1M | 1W |
|---|---|---|---|---|---|---|
|
IMDX
Insight Molecular Diagnostics Inc.
Primary
|
-97.0% | -53.0% | +9.3% | -18.5% | -39.6% | -15.7% |
|
BDSX
Biodesix, Inc.
Peer
|
-97.8% | -75.2% | -34.9% | +31.6% | +72.1% | +49.0% |
|
DH
Definitive Healthcare Corp.
Peer
|
-97.5% | -89.8% | -57.4% | -66.5% | -13.7% | -13.0% |
|
GOSS
Gossamer Bio, Inc.
Peer
|
-95.6% | -66.2% | -57.8% | -85.5% | -26.7% | +0.4% |
|
FONR
FONAR Corporation
Peer
|
+3.3% | +15.4% | +48.2% | +20.1% | +0.7% | +0.1% |
Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.
Historical Performance Trends
Long-term financial metrics and growth patterns
Revenue & Net Income
Profit & Operating Margins
Return on Equity (ROE)
Quarterly Revenue Growth
Valuation Metrics
Key valuation ratios and pricing indicators
Profitability
Profit margins and return metrics
Growth
Revenue and earnings growth rates
Financial Health
Balance sheet strength and liquidity metrics
Financial Statement Flow
Interactive flow visualization showing how money moves through the company Q4 2025
Quarterly Earnings History
EPS performance vs analyst estimates
Healthcare Sector Comparison
Similar Companies
Peer comparison within the same industry
| Company | AI Rating | Market Cap | P/E | ROE | Profit Margin | Price | |
|---|---|---|---|---|---|---|---|
|
IMDX
Insight Molecular Diagnostics Inc.
|
BEARISH | $101.97M | - | -% | -% | $3.17 | |
|
BDSX
Biodesix, Inc.
|
BEARISH | $93.92M | - | -302.6% | -49.3% | $11.74 | Compare |
|
DH
Definitive Healthcare Corp.
|
NEUTRAL | $111.79M | - | -40.4% | -57.5% | $1.07 | Compare |
|
GOSS
Gossamer Bio, Inc.
|
BEARISH | $87.21M | - | -% | -% | $0.37 | Compare |
|
FONR
FONAR Corporation
|
NEUTRAL | $117.26M | 16.18 | 6.0% | 7.1% | $18.61 | Compare |
Recent Insider Trading
Insider buy and sell transactions from the last 6 months
| Date | Insider | Position | Transaction | Shares | Value |
|---|---|---|---|---|---|
| 2026-03-26 | LIU JAMES YANG | Officer and Treasurer | Stock Award | 6,289 | - |
| 2026-03-26 | RIGGS JOSHUA | Chief Executive Officer | Stock Award | 47,170 | - |
| 2026-03-26 | JAMES ANDREA S. | Chief Financial Officer | Stock Award | 28,302 | - |
| 2026-02-10 | BROADWOOD PARTNERS, L.P. | Beneficial Owner of more than 10% of a Class of Security | Purchase | 521,739 | $3,866,086 |
| 2025-10-31 | JAMES ANDREA S. | Chief Financial Officer | Stock Award | 50,000 | - |
| 2025-10-31 | JAMES ANDREA S. | Chief Financial Officer | Stock Award | 50,000 | - |
Wall Street Analysts
Professional analyst ratings and price targets
Past News Coverage
Recent headlines mentioning IMDX from our newsroom.